{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T15:23:52Z","timestamp":1761578632079,"version":"3.37.3"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T00:00:00Z","timestamp":1527120000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81000288","81270842"],"award-info":[{"award-number":["81000288","81270842"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s00432-018-2664-y","type":"journal-article","created":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T10:08:44Z","timestamp":1527156524000},"page":"1751-1768","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Effectiveness and tolerability of targeted drugs for the treatment of metastatic castration-resistant prostate cancer: a network meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"144","author":[{"given":"Yongquan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2800-6220","authenticated-orcid":false,"given":"Zhansong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,24]]},"reference":[{"key":"2664_CR1","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/S1470-2045(13)70479-0","volume":"14","author":"JC Araujo","year":"2013","unstructured":"Araujo JC, Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J et al (2013) Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol 14:1307\u20131316","journal-title":"Lancet Oncol"},{"key":"2664_CR2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1200\/JCO.2016.69.1584","volume":"35","author":"TM Beer","year":"2017","unstructured":"Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G et al (2017a) Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol 35:40\u201347","journal-title":"J Clin Oncol"},{"issue":"2","key":"2664_CR3","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.eururo.2016.07.032","volume":"71","author":"TM Beer","year":"2017","unstructured":"Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS et al (2017b) Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL Study. Eur Urol 71(2):151\u2013154","journal-title":"Eur Urol"},{"key":"2664_CR4","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1002\/pros.23236","volume":"76","author":"R Cathomas","year":"2016","unstructured":"Cathomas R, Crabb SJ, Mark M, Winterhalder R, Rothermundt C, Elliott T et al (2016) Orteronel switch maintenance therapy in metastatic castration resistant prostate cancer after first-line docetaxel: a multicenter, randomized, double-blind, placebo-controlled trial (SAKK 08\/11). Prostate 76:1519\u20131527","journal-title":"Prostate"},{"key":"2664_CR5","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/pros.23309","volume":"77","author":"A Chopra","year":"2017","unstructured":"Chopra A, Georgieva M, Lopes G, Yeo CM, Haaland B (2017) Abiraterone or enzalutamide in advanced castration-resistant prostate cancer: an indirect comparison. Prostate 77:639\u2013646","journal-title":"Prostate"},{"key":"2664_CR6","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.ejca.2009.12.014","volume":"46","author":"J Ferlay","year":"2010","unstructured":"Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46:765\u2013781","journal-title":"Eur J Cancer"},{"key":"2664_CR7","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","volume":"13","author":"K Fizazi","year":"2012","unstructured":"Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ et al (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13:983\u2013992","journal-title":"Lancet Oncol"},{"key":"2664_CR8","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1200\/JCO.2012.46.4149","volume":"31","author":"K Fizazi","year":"2013","unstructured":"Fizazi K, Higano CS, Nelson JB, Gleave M, Miller K, Morris T et al (2013) Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 31:1740\u20131747","journal-title":"J Clin Oncol"},{"key":"2664_CR9","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1200\/JCO.2014.56.5119","volume":"33","author":"K Fizazi","year":"2015","unstructured":"Fizazi K, Jones R, Oudard S, Efstathiou E, Saad F, de Wit R et al (2015) Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. J Clin Oncol 33:723\u2013731","journal-title":"J Clin Oncol"},{"key":"2664_CR10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cct.2015.03.005","volume":"42","author":"T Greco","year":"2015","unstructured":"Greco T, Edefonti V, Biondi-Zoccai G, Decarli A, Gasparini M, Zangrillo A et al (2015) A multilevel approach to network meta-analysis within a frequentist framework. Contemp Clin Trials 42:51\u201359","journal-title":"Contemp Clin Trials"},{"key":"2664_CR11","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1093\/annonc\/mds505","volume":"24","author":"A Heidenreich","year":"2013","unstructured":"Heidenreich A, Rawal SK, Szkarlat K, Bogdanova N, Dirix L, Stenzl A et al (2013) A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human \u03b1\u03bd integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer. Ann Oncol 24:329\u2013336","journal-title":"Ann Oncol"},{"key":"2664_CR12","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD et al (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928","journal-title":"BMJ"},{"key":"2664_CR13","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1158\/1078-0432.CCR-15-2512","volume":"22","author":"M Hussain","year":"2016","unstructured":"Hussain M, Le Moulec S, Gimmi C, Bruns R, Straub J, Miller K (2016) Differential effect on bone lesions of targeting integrins: randomized phase II trial of abituzumab in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 22:3192\u20133200","journal-title":"Clin Cancer Res"},{"key":"2664_CR14","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162:777\u2013784","journal-title":"Ann Intern Med"},{"key":"2664_CR15","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1111\/j.1464-410X.2010.09638.x","volume":"106","author":"ND James","year":"2010","unstructured":"James ND, Caty A, Payne H, Borre M, Zonnenberg BA, Beuzeboc P et al (2010) Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized phase II trial. BJU Int 106:966\u2013973","journal-title":"BJU Int"},{"key":"2664_CR16","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1200\/JCO.2011.39.4767","volume":"30","author":"WK Kelly","year":"2012","unstructured":"Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, Stadler WM et al (2012) Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 30:1534\u20131540","journal-title":"J Clin Oncol"},{"key":"2664_CR17","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","volume":"15","author":"ED Kwon","year":"2014","unstructured":"Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ et al (2014) Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 15:700\u2013712","journal-title":"Lancet Oncol"},{"key":"2664_CR18","doi-asserted-by":"publisher","first-page":"e0145066","DOI":"10.1371\/journal.pone.0145066","volume":"10","author":"D Li","year":"2015","unstructured":"Li D, Wang T, Shen S, Cheng S, Yu J, Zhang Y et al (2015) Effects of fluroquinolones in newly diagnosed, sputum-positive tuberculosis therapy: a systematic review and network meta-analysis. PLoS One 10:e0145066","journal-title":"PLoS One"},{"key":"2664_CR19","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1200\/JCO.2012.48.5268","volume":"32","author":"MD Michaelson","year":"2014","unstructured":"Michaelson MD, Oudard S, Ou YC, Sengelov L, Saad F, Houede N et al (2014) Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J Clin Oncol 32:76\u201382","journal-title":"J Clin Oncol"},{"key":"2664_CR20","doi-asserted-by":"publisher","first-page":"5709","DOI":"10.1002\/cncr.27674","volume":"118","author":"JB Nelson","year":"2012","unstructured":"Nelson JB, Fizazi K, Miller K, Higano C, Moul JW, Akaza H et al (2012) Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. Cancer 118:5709\u20135718","journal-title":"Cancer"},{"key":"2664_CR21","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1200\/JCO.2015.64.9285","volume":"34","author":"DF Penson","year":"2016","unstructured":"Penson DF, Armstrong AJ, Concepcion R, Agarwal N, Olsson C, Karsh L et al (2016) Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE trial. J Clin Oncol 34:2098\u20132106","journal-title":"J Clin Oncol"},{"key":"2664_CR22","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1470-2045(15)70025-2","volume":"16","author":"DP Petrylak","year":"2015","unstructured":"Petrylak DP, Vogelzang NJ, Budnik N, Wiechno PJ, Sternberg CN, Doner K et al (2015) Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 16:417\u2013425","journal-title":"Lancet Oncol"},{"key":"2664_CR23","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1200\/JCO.2011.35.6295","volume":"29","author":"R Pili","year":"2011","unstructured":"Pili R, Haggman M, Stadler WM, Gingrich JR, Assikis VJ, Bjork A et al (2011) Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol 29:4022\u20134028","journal-title":"J Clin Oncol"},{"key":"2664_CR24","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/bju.13764","volume":"119","author":"MHF Poorthuis","year":"2017","unstructured":"Poorthuis MHF, Vernooij RWM, van Moorselaar RJA, de Reijke TM (2017) First-line non-cytotoxic therapy in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of 10 randomised clinical trials. BJU Int 119:831\u2013845","journal-title":"BJU Int"},{"key":"2664_CR25","doi-asserted-by":"publisher","first-page":"8177","DOI":"10.7314\/APJCP.2014.15.19.8177","volume":"15","author":"WX Qi","year":"2014","unstructured":"Qi WX, Fu S, Zhang Q, Guo XM (2014) Efficacy and toxicity of anti-VEGF agents in patients with castration-resistant prostate cancer: a meta-analysis of prospective clinical studies. Asian Pac J Cancer Prev 15:8177\u20138182","journal-title":"Asian Pac J Cancer Prev"},{"key":"2664_CR26","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1179\/1973947814Y.0000000230","volume":"27","author":"WX Qi","year":"2015","unstructured":"Qi WX, Fu S, Zhang Q, Guo XM (2015) Efficacy and toxicity of molecular targeted therapies in combination with docetaxel for metastatic castration-resistant prostate cancer: a meta-analysis of phase III randomized controlled trials. J Chemother 27:181\u2013187","journal-title":"J Chemother"},{"key":"2664_CR27","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/S1470-2045(13)70294-8","volume":"14","author":"DI Quinn","year":"2013","unstructured":"Quinn DI, Tangen CM, Hussain M, Lara PN Jr, Goldkorn A, Moinpour CM et al (2013) Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol 14:893\u2013900","journal-title":"Lancet Oncol"},{"key":"2664_CR28","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.critrevonc.2016.02.013","volume":"101","author":"G Roviello","year":"2016","unstructured":"Roviello G, Sigala S, Danesi R, Re MD, Bonetta A, Cappelletti MR et al (2016a) Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: a meta-analysis of published trials. Crit Rev Oncol Hematol 101:12\u201320","journal-title":"Crit Rev Oncol Hematol"},{"key":"2664_CR29","doi-asserted-by":"publisher","first-page":"e4636","DOI":"10.1097\/MD.0000000000004636","volume":"95","author":"G Roviello","year":"2016","unstructured":"Roviello G, Cappelletti MR, Zanotti L, Gobbi A, Senti C, Bottini A et al (2016b) Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trials. Medicine (Baltimore) 95:e4636","journal-title":"Medicine (Baltimore)"},{"key":"2664_CR30","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ejca.2016.04.002","volume":"61","author":"G Roviello","year":"2016","unstructured":"Roviello G, Sigala S, Sandhu S, Bonetta A, Cappelletti MR, Zanotti L et al (2016c) Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials. Eur J Cancer 61:111\u2013121","journal-title":"Eur J Cancer"},{"key":"2664_CR31","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","volume":"16","author":"CJ Ryan","year":"2015","unstructured":"Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN et al (2015) Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16:152\u2013160","journal-title":"Lancet Oncol"},{"key":"2664_CR32","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/S1470-2045(15)70027-6","volume":"16","author":"F Saad","year":"2015","unstructured":"Saad F, Fizazi K, Jinga V, Efstathiou E, Fong PC, Hart LL et al (2015) Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. Lancet Oncol 16:338\u2013348","journal-title":"Lancet Oncol"},{"key":"2664_CR33","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187\u20131197","journal-title":"N Engl J Med"},{"key":"2664_CR34","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S1470-2045(15)00518-5","volume":"17","author":"ND Shore","year":"2016","unstructured":"Shore ND, Chowdhury S, Villers A, Klotz L, Siemens DR, Phung et al (2016) Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Lancet Oncol 17:153\u2013163","journal-title":"Lancet Oncol"},{"key":"2664_CR35","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1093\/annonc\/mdr555","volume":"23","author":"G Sonpavde","year":"2012","unstructured":"Sonpavde G, Matveev V, Burke JM, Caton JR, Fleming MT, Hutson TE et al (2012) Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. Ann Oncol 23:1803\u20131808","journal-title":"Ann Oncol"},{"key":"2664_CR36","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2016.66.9697","volume":"34","author":"C Sternberg","year":"2016","unstructured":"Sternberg C, Armstrong A, Pili R, Ng S, Huddart R, Agarwal N et al (2016) Randomized, double-blind, placebo-controlled phase III study of tasquinimod in men with metastatic castration-resistant prostate cancer. J Clin Oncol 34:2636\u20132643","journal-title":"J Clin Oncol"},{"key":"2664_CR37","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/iju.13051","volume":"23","author":"Y Sun","year":"2016","unstructured":"Sun Y, Zou Q, Sun Z, Li C, Du C, Chen Z et al (2016) Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study. Int J Urol 23:404\u2013411","journal-title":"Int J Urol"},{"key":"2664_CR38","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S1470-2045(13)70184-0","volume":"14","author":"IF Tannock","year":"2013","unstructured":"Tannock IF, Fizazi K, Ivanov S, Karlsson CT, Flechon A, Skoneczna I et al (2013) Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol 14:760\u2013768","journal-title":"Lancet Oncol"},{"key":"2664_CR39","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1126\/science.1168175","volume":"324","author":"C Tran","year":"2009","unstructured":"Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V et al (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324:787\u2013790","journal-title":"Science"},{"key":"2664_CR40","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/1471-2288-12-150","volume":"12","author":"L Trinquart","year":"2012","unstructured":"Trinquart L, Chatellier G, Ravaud P (2012) Adjustment for reporting bias in network meta-analysis of antidepressant trials. BMC Med Res Methodol 12:150","journal-title":"BMC Med Res Methodol"},{"key":"2664_CR41","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1200\/JCO.2017.72.8030","volume":"35","author":"KS Virgo","year":"2017","unstructured":"Virgo KS, Basch E, Loblaw DA, Oliver TK, Rumble RB, Carducci MA et al (2017) Second-line hormonal therapy for men with chemotherapy-naive, castration-resistant prostate cancer: American society of clinical oncology provisional clinical opinion. J Clin Oncol 35:1952\u20131964","journal-title":"J Clin Oncol"},{"key":"2664_CR42","first-page":"3291","volume":"18","author":"Y Wu","year":"2014","unstructured":"Wu Y, Shao N, Shen ZX, Li Q, Wang Y, Li C et al (2014) The efficacy and safety of zibotentan in the treatment of castration-resistant prostate cancer: a meta-analysis. Eur Rev Med Pharmacol Sci 18:3291\u20133296","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2664_CR43","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s11934-010-0104-x","volume":"11","author":"L Zarour","year":"2010","unstructured":"Zarour L, Alumkal J (2010) Emerging therapies in castrate-resistant prostate cancer. Curr Urol Rep 11:152\u2013158","journal-title":"Curr Urol Rep"},{"key":"2664_CR44","doi-asserted-by":"publisher","first-page":"196","DOI":"10.4103\/1008-682X.178483","volume":"19","author":"W Zhang","year":"2017","unstructured":"Zhang W, Wu TY, Chen Q, Shi XL, Xiao GA, Zhao L et al (2017) Indirect comparison between abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review. Asian J Androl 19:196\u2013202","journal-title":"Asian J Androl"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-018-2664-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-018-2664-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-018-2664-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T19:14:49Z","timestamp":1558638889000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-018-2664-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,24]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["2664"],"URL":"https:\/\/doi.org\/10.1007\/s00432-018-2664-y","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"type":"print","value":"0171-5216"},{"type":"electronic","value":"1432-1335"}],"subject":[],"published":{"date-parts":[[2018,5,24]]},"assertion":[{"value":"20 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}